Adirondack Trust Co. Has $144,000 Position in Celgene Co. (NASDAQ:CELG)
Adirondack Trust Co. trimmed its stake in shares of Celgene Co. (NASDAQ:CELG) by 29.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,521 shares of the biopharmaceutical company’s stock after selling 630 shares during the quarter. Adirondack Trust Co.’s holdings in Celgene were worth $144,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in CELG. Capital Management Corp VA bought a new position in Celgene in the 1st quarter worth about $10,955,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its stake in Celgene by 36.9% in the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 342,301 shares of the biopharmaceutical company’s stock worth $21,938,000 after acquiring an additional 92,209 shares during the last quarter. Tibra Equities Europe Ltd bought a new position in Celgene in the 1st quarter worth about $6,396,000. Global Trust Asset Management LLC increased its stake in Celgene by 212.3% in the 1st quarter. Global Trust Asset Management LLC now owns 4,557 shares of the biopharmaceutical company’s stock worth $430,000 after acquiring an additional 3,098 shares during the last quarter. Finally, MML Investors Services LLC increased its stake in Celgene by 7.9% in the 4th quarter. MML Investors Services LLC now owns 35,014 shares of the biopharmaceutical company’s stock worth $2,244,000 after acquiring an additional 2,555 shares during the last quarter. Institutional investors own 75.19% of the company’s stock.
A number of equities analysts have weighed in on the company. ValuEngine upgraded Celgene from a “sell” rating to a “hold” rating in a research note on Saturday, May 4th. BidaskClub lowered Celgene from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Barclays lowered Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price on the stock. in a research note on Friday, May 3rd. Mizuho set a $103.00 target price on Celgene and gave the stock a “buy” rating in a research note on Friday, April 5th. Finally, Cantor Fitzgerald lowered Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 target price on the stock. in a research note on Friday, April 5th. Eighteen research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $95.56.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.45 by $0.10. The firm had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.01 billion. Celgene had a return on equity of 106.69% and a net margin of 30.10%. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period in the prior year, the business earned $2.05 EPS. As a group, equities research analysts expect that Celgene Co. will post 9.85 EPS for the current year.
WARNING: This report was first published by Marea Informative and is the sole property of of Marea Informative. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.mareainformativa.com/news/2019/06/13/adirondack-trust-co-has-144000-position-in-celgene-co-nasdaqcelg.html.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Recommended Story: Why is a lock-up period needed for an IPO?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.